Kwality Pharmaceuticals Q1 FY27 Results: Revenue Rs 162 Cr, PAT Rs 25 Cr and Key Highlights
- August 11, 2026
- Posted by: Kunal Singla
- Category: News
Kwality Pharmaceuticals Q1 FY27 results declared August 10, 2026. Revenue Rs 162 Cr (+45.63% YoY). PAT Rs 25 Cr (+114.96% YoY). CMP Rs 3134.1 (+20.0%).
Kwality Pharmaceuticals Q1 FY27 results were declared on August 10, 2026 on a consolidated basis. Revenue expanded +45.63% YoY to Rs 162 Cr from Rs 111 Cr in Q1 FY26. The broader Nifty Pharma index reflected mixed sentiment during the quarter.
Operating profit stood at Rs 36 Cr (+85.58% YoY). PAT came in at Rs 25 Cr (+114.96% YoY), reflecting the key financial metrics of Kwality Pharmaceuticals Q1 FY27 results.
Click Here – Get Free Investment Predictions
Kwality Pharmaceuticals Q1 FY27 Financial Highlights
| Metric | Q1 FY27 (Rs Cr) | Q1 FY26 (Rs Cr) | YoY Change |
|---|---|---|---|
| Kwality Pharmaceuticals Revenue | 162 | 111 | +45.63% |
| Operating Profit | 36 | 19 | +85.58% |
| Net Profit (PAT) | 25 | 11 | +114.96% |
| Reporting Basis | Consolidated | ||
Kwality Pharmaceuticals Q1 FY27 Performance Analysis
Check the Univest Screener for Live Data on This Stock
Kwality Pharmaceuticals Q1 FY27 results reflect exceptional fundamentals. Revenue momentum were evident with the top line reaching Rs 162 Cr for the April to June 2026 quarter.
Operating profit expanded +85.58% YoY. PAT of Rs 25 Cr reflects +114.96% YoY movement. Investors tracking Kwality Pharmaceuticals Q1 FY27 results will note these as key FY27 milestones.
Key Business Factors in Kwality Pharmaceuticals Q1 FY27 Results
Revenue Expansion in Q1 FY27
Kwality Pharmaceuticals Q1 FY27 results show revenue expanding +45.63% YoY to Rs 162 Cr from Rs 111 Cr in Q1 FY26. Volume-led growth and market share gains in the Pharmaceuticals segment drove the uptick.
Operating Margin Performance
Operating profit in Kwality Pharmaceuticals Q1 FY27 results stood at Rs 36 Cr (+85.58% YoY). Better cost absorption and product mix improvement contributed to the operating performance.
PAT Trajectory and Profitability
PAT in Kwality Pharmaceuticals Q1 FY27 results was Rs 25 Cr (+114.96% YoY), reflecting the company’s improving financial health.
Dividend Details
No dividend was declared alongside Kwality Pharmaceuticals Q1 FY27 results. Earnings are being channelled toward operational reinvestment and working capital.
FY27 Outlook for Kwality Pharmaceuticals
Kwality Pharmaceuticals is positioned to sustain growth momentum through FY27, backed by order visibility, operational improvements, and sector tailwinds in the pharmaceuticals space. Investors tracking Kwality Pharmaceuticals Q1 FY27 results should consult a SEBI-registered financial advisor before making decisions.
Kwality Pharmaceuticals Stock Performance After Q1 FY27 Results
Download the Univest iOS App or Univest Android App to track Kwality Pharmaceuticals live price and get daily stock recommendations.
Kwality Pharmaceuticals shares were trading higher at Rs 3134.1 (+20.0%) on August 10, 2026, reflecting investor sentiment on Kwality Pharmaceuticals Q1 FY27 results and the near-term sector outlook. The CMP of Rs 3134.1 on the results date reflects broader sentiment toward the pharmaceuticals space.
Key Risks for Kwality Pharmaceuticals
Sector-Specific Risks
USFDA regulatory actions, generic pricing pressure, and API cost inflation remain core risks.
Valuation and Earnings Risk
Valuation risk remains if quarterly growth fails to sustain over the next two to three quarters.
Operational and Financial Risk
Subsidiary-level underperformance could drag consolidated PAT lower in subsequent quarters.
Conclusion
Kwality Pharmaceuticals Q1 FY27 results reflect exceptional performance with revenue at Rs 162 Cr and PAT at Rs 25 Cr on a Consolidated basis. Sector tailwinds and operational discipline will shape the FY27 trajectory. Investors should review management commentary before taking any position.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Kwality Pharmaceuticals Q1 FY27 Results
When were Kwality Pharmaceuticals Q1 FY27 results declared?
Ans. Kwality Pharmaceuticals Q1 FY27 results were declared on August 10, 2026, covering the April–June 2026 quarter on a Consolidated basis.
What was Kwality Pharmaceuticals revenue in Q1 FY27?
Ans. Revenue in Kwality Pharmaceuticals Q1 FY27 results was Rs 162 Cr, +45.63% YoY from Rs 111 Cr in Q1 FY26.
What was Kwality Pharmaceuticals PAT in Q1 FY27?
Ans. Net profit in Kwality Pharmaceuticals Q1 FY27 results was Rs 25 Cr (+114.96% YoY).
Did Kwality Pharmaceuticals declare a dividend in Q1 FY27?
Ans. No dividend was announced alongside Kwality Pharmaceuticals Q1 FY27 results. Refer to official NSE and BSE announcements for future dividend updates.
What is the FY27 outlook for Kwality Pharmaceuticals?
Ans. Management has guided revenue growth and margin improvement for FY27. Sector demand and execution will be key monitorables.
How did Kwality Pharmaceuticals stock react to Q1 FY27 results?
Ans. Kwality Pharmaceuticals shares were higher at Rs 3134.1 (+20.0%) on August 10, 2026. Consult a SEBI-registered financial advisor before acting on price movements.
